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Abstract 
 
Objective: Though thrombocytopenia is a known adverse effect with linezolid, the first-in class 
oxazolidinone antibiotic, some have suggested a lower risk of thrombocytopenia with tedizolid, 
the second-in-class oxazolidinone antibiotic. We sought to evaluate adverse event reports for 
thrombocytopenia with tedizolid and linezolid from the Food and Drug Administration Adverse 
Event Reporting System (FAERS). 
  
Methods: To assess the period since tedizolid approval, we included initial FAERS reports from 
July 2014 through December 2016. To evaluate historical rates with linezolid prior to tedizolid 
approval, we assessed AERSMine data from January 2004 through June 2014. Reporting odds 
ratios (ROR) and proportional reporting ratios (PRR) were calculated. 
  
Results: Of all the reported events, 0.074% (n=1,468) were thrombocytopenia. Linezolid 
represented 0.02% (n=408) of all events, and tedizolid represented 0.002% (n=41). The ROR 
for thrombocytopenia with linezolid was 37.9 (95% confidence interval [CI] 20.78-69.17) and 
with tedizolid was 34.0 (95% CI 4.67- 247.30). The PRR for thrombocytopenia with linezolid was 
36.9 (95% CI 20.56-66.28) and with tedizolid was 33.2 (95% CI 4.79- 230.10). From 2004 
through June 2014, the linezolid ROR was 12.1 (95% CI 11.19-12.96) and PRR was 11.1 (95% 
CI 10.38-11.87).  
 
Conclusion: We observed a significantly increased risk of thrombocytopenia of similar 
magnitude with both linezolid and tedizolid. Thrombocytopenia with tedizolid should be 
assessed with real-world comparative safety studies as more patients are treated with tedizolid.  
 
  
Introduction 
Linezolid is an oxazolidinone antibiotic that was approved by the Food and Drug Administration 
(FDA) in April 2000. Tedizolid, a second-in-class oxazolidinone antibiotic, was approved in June 
2014. Linezolid’s FDA approved indications include vancomycin-resistant Enterococcus faecium 
infections, nosocomial pneumonia, complicated skin and skin structure infections, including 
diabetic foot infections without concomitant osteomyelitis, uncomplicated skin and skin structure 
infections, and community-acquired pneumonia (1). Tedizolid’s FDA approved indications 
include acute bacterial skin and skin structure infections (ABSSSI) (2). 
 
As tedizolid has only been on the market for 3 years, adverse events during real-world use are 
still being discovered and studied. Though thrombocytopenia is a known side effect with 
linezolid as noted in the Warnings and Precautions section of the label, the package insert for 
tedizolid does not include such a warning (3, 4). In a pooled analysis of two phase 3, double-
blind, randomized, comparator-controlled trials in patients with ABSSSI, rates of 
thrombocytopenia were found to be lower with tedizolid as compared with linezolid (5). 
Subsequently, review articles have cited this finding, suggesting a lower risk of 
thrombocytopenia with tedizolid (6, 7). Therefore, we sought to determine whether rates of 
thrombocytopenia adverse event reporting were lower with tedizolid than with linezolid. 
 
Methods 
We reviewed adverse event reports from the FDA Adverse Event Reporting System (FAERS) 
for the time period of July 2014 through December 2016 (8). Follow-up reports and reports 
missing all three categories of event date, sex, and age were excluded. A broad search term for 
thrombocytopenia was used and subsequent listings of adverse events were reviewed for 
inclusion. To evaluate adverse events reports for thrombocytopenia with linezolid before 
tedizolid was approved, we used AERSMine with a restricted time period of January 2004 
through June 2014 (9). Using a case-non-case design, reporting odds ratios (ROR) and 
proportional reporting ratios (PRR), and corresponding 95% confidence intervals (CI) were 
calculated with OpenEpi (10-12). 
 
Results 
There were 1,995,573 adverse events that fit the defined criteria from July 2014 through 
December 2016 (Table 1). Of these adverse events, 0.07% (n=1,468) were thrombocytopenia. 
Among all adverse events, 0.02% (n=408) were from linezolid and 0.002% (n=41) were from 
tedizolid. Thrombocytopenia represented 2.70% (n=11) of the adverse events for linezolid and 
2.44% (n=1) for tedizolid. The ROR for thrombocytopenia with linezolid was 37.9 (95% CI 
20.78-69.17) and with tedizolid was 34.0 (95% CI 4.67- 247.30). The PRR for thrombocytopenia 
with linezolid was 36.9 (95% CI 20.56-66.28) and with tedizolid was 33.2 (95% CI 4.79- 230.10).  
 
In the analysis of thrombocytopenia with linezolid prior to the approval of tedizolid using 
AERSmine from 2004 through June 2014, there were 5,818,659 adverse events that were 
reported. Of these adverse events, 0.79% (n=45,701) were thrombocytopenia and among all 
adverse events 0.16% (n=9,267) included linezolid. There were 795 cases of thrombocytopenia 
reported with linezolid, resulting in a ROR of 12.1 (95% CI 11.19-12.96) and PRR of 11.1 (95% 
CI 10.38-11.87).  
 
Discussion 
Based on our analysis of adverse event reports from the real-world clinical use of linezolid and 
tedizolid, both antibiotics were associated with a significantly increased risk of thrombocytopenia 
and this risk was of similar magnitude. Since it is recognized that adverse event reporting to 
FAERS is higher in the years following drug approval, we assessed two time periods, the period 
since tedizolid approval, and a ten year period prior to the approval of tedizolid (13). In the 
tedizolid post-approval period, the risk of thrombocytopenia was over 30 times higher with both 
tedizolid and linezolid as compared with adverse event reports from other medications. In the 
period prior to tedizolid approval, the risk of thrombocytopenia was 12 times higher with linezolid 
(5, 14). 
 
Our study assessed thrombocytopenia from adverse events terms (Medical Dictionary for 
Regulatory Activities, MedDRA), however clinical trials have used various platelet count 
thresholds to define this adverse event (8). A “substantially low platelet count” has been defined 
as <75% of the lower limit of normal or baseline, where the lower limit of normal (LLN) is 
150,000 cells/mm3, resulting in a platelet count of 112,500 cells/mm3 (3, 5, 15). However, a 
lower threshold of less than 100,000 cells/mm3 is considered clinically relevant and has been 
used to operationally define thrombocytopenia (5, 14). 
 
Rates of thrombocyotopenia from previous clinical trials, though numerically higher with 
linezolid, were not statistically significantly higher compared with tedizolid. Both trials assessed 
the efficacy and safety of 6-day oral and/or intravenous tedizolid in acute bacterial skin and skin 
structure infections versus 10-day oral and/or intravenous linezolid therapy (ESTABLISH-1 and 
ESTABLISH-2, NCT01170221 and NCT01421511 as registered at ClinicalTrials.gov) (15, 16). 
In the safety analysis set from ESTABLISH-1, substantially low platelet counts (<75% of the 
LLN/baseline) were observed in 2.3% of patients in the tedizolid group (n=331) and 4.9% of 
patients in the linezolid group (n=335) (15). It was noted that half of the patients with 
thrombocytopenia (11/22) also had hepatitis C. Though there were more patients in the linezolid 
group with hepatitis C (tedizolid 101/329, 30.7%; linezolid 116/327, 35.5%; p=0.19), the 
distribution of hepatitis C plus thrombocytopenia by treatment group was not presented.  
 
ESTABLISH-2 only presented platelet counts less than the LLN (<150,000 cells/mm3) instead of 
less than 75% of the LLN/baseline (<112,500 cells/mm3) as reported from ESTABLISH-1. 
Therefore, event rates were higher in ESTABLISH-2 but still not significantly different (tedizolid 
27/314, 9%; linezolid 41/305, 13%; p=0.07). Again, hepatitis C was slightly more common in the 
linezolid group (tedizolid 65/322, 20%; linezolid 80/321, 25%; p=0.15), however the distribution 
of hepatitis C plus thrombocytopenia by treatment group was not presented. 
 
A significant difference in thrombocytopenia was not observed until data from ESTABLISH-1 
and ESTABLISH-2 were pooled. A significant difference between groups was observed using 
two definitions of thrombocytopenia (<150,000 cells/mm3, <100,000 cells/mm3) during study 
days 11-13 days but not during study days 7-9 (5). A limitation of this pooled analysis was that 
tedizolid therapy ended on day 6, while linezolid therapy ended on day 10. Additionally, this was 
a pooled analysis of clinical trial data, which does not confer the same benefits as a meta-
analysis of randomized data (17). In the real-world clinical setting, duration of exposure will be 
important to consider as comparative safety is assessed, particularly if duration for either or both 
antibiotics is shorter than the duration used in clinical trials. 
 
A possible explanation for the observed differences in thrombocytopenia form clinical trials may 
relate to the difference in metabolism and excretion with these two antibiotics (18). The majority 
of tedizolid is metabolized through the liver (82%), and less so through the kidneys (18%), while 
30% of linezolid is excreted through urine (3, 4). Studies suggest that for linezolid, the risk of 
thrombocytopenia might arise from its increased exposure in renal insufficient patients (19-21). 
Due to linezolid’s metabolite accumulation, renal dysfunction may become more severe 
resulting in higher metabolite levels than those with normal kidney function. Tedizolid is 
predominantly eliminated through the fecal route as tedizolid sulfate (18). The involvement of 
metabolites in thrombocytopenia however, is still unclear (20).  
 There are some limitations with our study. The true incidence of adverse events with tedizolid 
and linezolid are not known. Due the nature of FAERS reporting, which is not mandatory in all 
cases, incidence cannot be estimated. Additionally, FAERS data is subject to different sources 
of bias such as over reporting, underreporting, and missing information (13). Further limitations 
include the use of MedDRA terms for defining thrombocytopenia, since platelet counts/changes 
were not available, and reports with other adverse event terms which did not specifically 
mention thrombocytopenia were not included. As there was only one report of thrombocytopenia 
with tedizolid, the confidence intervals of the ROR and PRR were large and though statistically 
significant, the magnitude of the lower end of the confidence interval did vary between linezolid 
(~20 times higher risk) and tedizolid (~4 times higher risk). Lastly, FDA FAERS data was not 
available for the first several years after linezolid approval (April 2000 through December 2003), 
and therefore this initial time period could not be assessed for linezolid. 
 
Conclusions 
Though several publications have suggested a lower risk of thrombocytopenia with tedizolid, 
using FDA FAERS data, we observed a significantly increased risk of thrombocytopenia of 
similar magnitude with both linezolid and tedizolid. The incidence of thrombocytopenia in 
linezolid clinical trials was low, affecting only 2.2% of patients (22). Much higher rates were 
observed in real-world studies in the two years following drug approval, which ranged from 19-
32%, with 47-48% of patients experiencing greater than a 30% reduction in platelet count (14, 
23). Based on this previous experience, thrombocytopenia with tedizolid should be monitored 
and event rates should be assessed with real-world comparative safety studies as more patients 
are treated with tedizolid.  
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Table 1. Thrombocytopenia from adverse event reports 
 
  All adverse 
events 
Thrombocytop
enia 
Reporting odds 
ratio (95% 
confidence 
interval) 
Proportional 
reporting ratio 
(95% confidence 
interval) 
All medications,  
07/2014-12/2016 
1,995,573 1,468 (0.07%) -- -- 
Linezolid 408 11 (2.70%) 
37.9 (20.78-
69.17) 
36.9 (20.56-
66.28) 
Tedizolid 41 1 (2.44%) 
34.0 (4.67-
247.30) 
33.2 (4.79-
230.10) 
All medications,  
01/2004-06/2014 
5,772,958 45,701 (0.79%) -- -- 
Linezolid 9,267 795 (8.58%) 
12.1 (11.19-
12.96) 
11.1 (10.38-
11.87) 
 
 
 
